Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) stock price

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) is a Healthcare · Medical Distribution company listed on NASDAQ. Price $0.11 (-7.11%), Market cap $0.01B, 52-week low–high $0.51 ~ $2.15.

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers custom clearance, drugs enlisting, warehouse, and other logistics services. The company serves e-commerce platform logistics partners, merchants, and pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares are updated in real time on BlackAll Trade.

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares financial summary

Key ratios · profitability · growth

Frequently asked questions

What is the current Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) stock price?

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares trades at $0.11 (-7.11%). Real-time quotes and charts are available on BlackAll Trade.

What is the Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) market cap?

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares has a market cap of about $0.01B.

What does Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) do?

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cr